Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells

Clinical Immunology

Volumn 115, Issue 3, 2005, Pages 240-249

  Özdemir, Öner ^a,b   Savaşan, Süreyya ^a,c  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Cell mediated cytotoxicity; Cytotoxic NK T cell; Flow cytometric cell mediated cytotoxicity assay; Granzyme B; IL 2 and IL 15 combination; Interferon ; Leukemia lymphoma cells; NK LAK activity; Perforin; Tumor necrosis factor

Indexed keywords

CD56 ANTIGEN; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 2; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER CELL CULTURE; CELL POPULATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; KILLER CELL; LEUKEMIA CELL; LYMPHOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; T LYMPHOCYTE;

ADOLESCENT; ADULT; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; GRANZYMES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKEMIA; LYMPHOKINES; LYMPHOMA; MALE; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; SERINE ENDOPEPTIDASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19044364601     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2005.01.008     Document Type: Article

References (52)

1. T.A. Fehniger, and M.A. Caligiuri Interleukin 15: biology and relevance to human disease Blood 97 2001 14 32
2. S. Rutella, L. Pierelli, G. Bonanno, A. Mariotti, S. Sica, and F. Sora Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions Exp. Hematol. 29 2001 1503 1516
3. A. Eisenthal, O. Marder, B. Maymon, F. Misonzhnik, Y. Skornick, and E. Brazowski The effect of interferon-gamma and tumor necrosis factor-alpha on the expression of ICAM-1 and HLA-DR molecules on cells of a human germ cell neoplasm and their susceptibility to lysis by lymphokine-activated killer cells Pathobiology 66 1998 205 208
4. E.A. Grimm, A. Mazumder, H.Z. Zhang, and S.A. Rosenberg Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes J. Exp. Med. 155 1982 1823 1841
5. T. Ohkawa, S. Seki, H. Dobashi, Y. Koike, Y. Habu, and K. Ami Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells Immunology 103 2001 281 290
6. G.D. Schmidt-Wolf, R.S. Negrin, and I.G. Schmidt-Wolf Activated T cells and cytokine-induced CD3+CD56+ killer cells Ann. Hematol. 74 1997 51 56
7. M.R. Verneris, J. Baker, M. Edinger, and R.S. Negrin Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice J. Clin. Immunol. 22 2002 131 136
8. C.M. Mastroianni, G. d'Ettorre, G. Forcina, and V. Vullo Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy? Trends Immunol. 25 2004 121 125
9. E.Y. Woo, C.S. Chu, T.J. Goletz, K. Schlienger, H. Yeh, and G. Coukos Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer Cancer Res. 61 2001 4766 4772
10. M. Umemura, H. Nishimura, K. Saito, T. Yajima, G. Matsuzaki, and S. Mizuno Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guerin vaccination Infect. Immun. 71 2003 6045 6048
11. F. Nakajima, A. Khanna, G. Xu, M. Lagman, R. Haschemeyer, and J. Mouradian Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression Proc. Natl. Acad. Sci. U. S. A. 91 1994 7889 7893
12. J. Marks-Konczalik, S. Dubois, J.M. Losi, H. Sabzevari, N. Yamada, and L. Feigenbaum IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice Proc. Natl. Acad. Sci. U. S. A. 97 2000 11445 11450
13. Ö. Özdemir, Y. Ravindranath, and S. Savaşan Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine activated killer cells J. Immunother. 28 2005 44 52
14. Ö. Özdemir, S. Buck, Y. Ravindranath, W. Lyman, and S. Savaşan Interleukin-2 and interleukin-15 combination induces lymphokine-activated killer cells with higher perforin and granzyme-B expression patterns and superior cytotoxic response against human leukemia cells [Abstract] Blood 100 2002 471a
15. S. Barth, B. Kleinhappl, A. Gutschi, S. Jelovcan, and E. Marth In vitro cytokine mRNA expression in normal human peripheral blood mononuclear cells Inflamm. Res. 49 2000 266 274
16. P.M. Anderson, A.C. Ochoa, N.K. Ramsay, D. Hasz, and D. Weisdorf Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity Blood 80 1992 1846 1853
17. J. Lu, R.L. Giuntoli, R. Omiya, H. Kobayashi, R. Kennedy, and E. Celis Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes Clin. Cancer Res. 8 2002 3877 3884
18. Ö. Özdemir, Y. Ravindranath, and S. Savaşan Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with AnnexinV/Propidium Iodide co-labeling by fluorosphere-adjusted counts on three-color flow cytometry Cytometry 56A 2003 53 60
19. J.L. de Jong, N.L. Farner, B.R. Javorsky, M.J. Lindstrom, J.A. Hank, and P.M. Sondel Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy Clin. Cancer Res. 4 1998 1287 1296
20. F. Gesbert, M. Delespine-Carmagnat, and J. Bertoglio Recent advances in the understanding of interleukin-2 signal transduction J. Clin. Immunol. 18 1998 307 320
21. T.A. Fehniger, M.A. Cooper, and M.A. Caligiuri Interleukin-2 and interleukin-15: immunotherapy for cancer Cytokine Growth Factor Rev. 13 2002 169 183
22. M.R. Garovoy, and C.B. Carpenter Lymphocyte-mediated cytotoxicity N.R. Rose H. Friedman Manual of clinical immunology 2nd ed. 1980 American Society for Microbiology Washington, DC 290 296
23. P. Frost, C.P. Ng, A. Belldegrun, and B. Bonavida Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity Cell. Immunol. 180 1997 70 83
24. A.N. Liu, A.Z. Mohammed, W.R. Rice, D.T. Fiedeldey, J.S. Liebermann, and J.A. Whitsett Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand Am. J. Respir. Cell Mol. Biol. 20 1999 849 858
25. G. Caron, Y. Delneste, J.P. Aubry, G. Magistrelli, N. Herbault, and A. Blaecke Human NK cells constitutively express membrane TNF-α (mTNFα) and present mTNFα -dependent cytotoxic activity Eur. J. Immunol. 29 1999 3588 3595
26. M.R. Verneris, M. Ito, J. Baker, A. Arshi, R.S. Negrin, and J.A. Shizuru Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma Biol. Blood Marrow Transplant. 7 2001 532 542
27. D.G. Doherty, S. Norris, L.M. Estebas, G. McEntee, O. Traynor, and J.E. Hegarty The human liver contains multiple populations of NK Cells, T Cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns J. Immunol. 163 1999 2314 2321
28. W. Ye, J.D. Young, and C.C. Liu Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes Cell. Immunol. 174 1996 54 62
29. W. Munger, S.Q. DeJoy, R. Jeyaseelan Sr., L.W. Torley, K.H. Grabstein, and J. Eisenmann Studies evaluating the antitumor activity and toxicity of interleukin- 15, a new T cell growth factor: comparison with interleukin-2 Cell. Immunol. 165 1995 289 293
30. M.G. Seidel, M. Freissmuth, H. Pehamberger, and M. Micksche Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2 Naunyn-Schmiedeberg's Arch. Pharmacol. 358 1998 382 389
31. D. Xia, J. Wang, C. Shao, J. Shen, and J. Bao Study on the antitumor activity of CBMC activated by IL-12 alone or in combination with IL-2 Zhonghua Xue Ye Xue Za Zhi 21 2000 30 33
32. T. Yamaguchi, Y. Suzuki, R. Katakura, T. Ebina, J. Yokoyama, and Y. Fujimiya Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients Cancer Immunol. Immunother. 47 1998 97 103
33. D. Körholz, U. Banning, H. Bönig, M. Grewe, M. Schneider, and C. Mauz-Körholz The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses Blood 90 1997 4513 4521
34. S. Bulfone-Paus, H. Durkop, R. Paus, H. Krause, T. Pohl, and A. Onu Differential regulation of human T lymphoblast functions by IL-2 and IL-15 Cytokine 9 1997 507 513
35. R. Zambello, M. Facco, L. Trentin, R. Sancetta, C. Tassinari, and A. Perin Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes Blood 89 1997 201 211
36. W.E. Carson, J.G. Giri, M.J. Lindemann, M.L. Linett, M. Ahdieh, and R. Paxton Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor J. Exp. Med. 180 1994 1395 1403
37. W.E. Carson, T.A. Fehniger, S. Haldar, K. Eckhert, M.J. Lindemann, and C.F. Lai A potential role for interleukin-15 in the regulation of human natural killer cell survival J. Clin. Invest. 99 1997 937 943
38. S. Yamasaki, M. Maeda, K. Ohshima, M. Kikuchi, T. Otsuka, and M. Harada Growth and apoptosis of human natural killer cell neoplasms: role of interleukin-2/15 signaling Leuk. Res. 28 2004 1023 1031
39. H.S. Warren, B.F. Kinnear, R.L. Kastelein, and L.L. Lanier Analysis of the costimulatory role of IL-2 and IL-15 in initiating proliferation of resting (CD56dim) human NK cells J. Immunol. 156 1996 3254 3259
40. H. Azuma, Y. Yamada, N. Shibuya-Fujiwara, M. Yamaguchi, H. Murahashi, and M. Fujihara Functional evaluation of ex vivo expanded cord blood lymphocytes: possible use for adoptive cellular immunotherapy Exp. Hematol. 30 2002 346 351
41. + T cells proliferation but is unable to drive cytokine production in the absence of TCR activation or IL-12/IL-4 stimulation in vitro Eur. J. Immunol. 32 2002 341 347
42. T.A. Fehniger, M.H. Shah, M.J. Turner, J.B. VanDeusen, S.P. Whitman, and M.A. Cooper Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response J. Immunol. 162 1999 4511 4520
43. M. Togami, K. Yasumoto, T. Yano, T. Ishida, G. Kimura, and K. Sugimachi Studies of serum-free medium for the generation of lymphokine-activated killer cells Cytotechnology 6 1991 39 47
44. D.W. McVicar, F. Li, C.W. McCrady, and R.E. Merchant A comparison of serum-free media for the support of in vitro mitogen-induced blastogenic expansion of cytolytic lymphocytes Cytotechnology 6 1991 105 113
45. H.M. Jackson, N. Dimopoulos, Q. Chen, T. Luke, T.Y. Tai, and E. Maraskovsky A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples J. Immunol. Methods 291 2004 51 62
46. A.E. Trickett, Y.L. Kwan, B. Cameron, and J.M. Dwyer Ex vivo expansion of functional T lymphocytes from HIV-infected individuals J. Immunol. Methods 262 2002 71 83
47. S. Dubois, J. Mariner, T.A. Waldmann, and Y. Tagaya IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells Immunity 17 2002 537 547
48. P.R. Burkett, R. Koka, M. Chien, S. Chai, D.L. Boone, and A. Ma Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis J. Exp. Med. 200 2004 825 834
49. R. Koka, P. Burkett, M. Chien, S. Chai, D.L. Boone, and A. Ma Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells J. Immunol. 173 2004 3594 3598
50. H. Kobayashi, S. Dubois, N. Sato, H. Sabzevari, Y. Sakai, and T.A. Waldmann The role of trans-cellular IL-15-presentation in the activation of NK-mediated killing, which leads to enhanced tumor immunesurveillance Blood 2005 721 727
51. S. Roychowdhury, K.F. May Jr., K.S. Tzou, T. Lin, D. Bhatt, and A.G. Freud Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2 Cancer Res. 64 2004 8062 8067
52. C.A. Klebanoff, S.E. Finkelstein, D.R. Surman, M.K. Lichtman, L. Gattinoni, and M.R. Theoret IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 1969 1974